Ascendis Pharma A/S
ASND · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $560 | $392 | $445 | $446 |
| Short-Term Investments | $0 | $7 | $291 | $236 |
| Receivables | $166 | $36 | $12 | $2 |
| Inventory | $296 | $209 | $131 | $75 |
| Other Curr. Assets | $39 | $58 | $45 | $46 |
| Total Curr. Assets | $1,061 | $703 | $923 | $806 |
| Property Plant & Equip (Net) | $99 | $111 | $129 | $126 |
| Goodwill | $3 | $3 | $3 | $3 |
| Intangibles | $1 | $1 | $1 | $2 |
| Long-Term Investments | $14 | $6 | $30 | $146 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $2 | $2 | $2 | $2 |
| Total NC Assets | $119 | $123 | $166 | $279 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $1,179 | $826 | $1,090 | $1,085 |
| Liabilities | – | – | – | – |
| Payables | $96 | $95 | $101 | $59 |
| Short-Term Debt | $492 | $435 | $427 | $14 |
| Tax Payable | $1 | $2 | $5 | $0 |
| Deferred Revenue | $1 | $1 | $0 | $3 |
| Other Curr. Liab. | $318 | $203 | $183 | $24 |
| Total Curr. Liab. | $908 | $737 | $717 | $100 |
| LT Debt | $365 | $308 | $191 | $196 |
| Deferred Rev, NC | $5 | $6 | $14 | $3 |
| Deferred Tax Liab, NC | $7 | $6 | $0 | $0 |
| Other NC Liab. | $0 | -$85 | -$95 | -$98 |
| Total NC Liab. | $377 | $235 | $110 | $101 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $99 | $109 | $105 |
| Total Liabilities | $1,285 | $971 | $826 | $201 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $8 | $8 | $8 | $8 |
| Retained Earnings | -$2,560 | -$2,277 | -$1,860 | -$1,236 |
| AOCI | $2 | $1 | $3 | $4 |
| Other Equity | $2,444 | $2,123 | $2,113 | $2,108 |
| Total Equity | -$106 | -$146 | $263 | $884 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $1,179 | $826 | $1,090 | $1,085 |
| Net Debt | $297 | $351 | $173 | -$236 |